Novartis hands rights for 2 cancer drugs to Shanghai-based biotech

The licensing deal is Novartis' second with Laekna Therapeutics, and will give the pharma an equity stake in the Chinese company.

By Andrew Dunn • Aug. 1, 2018

Daiichi acquires another ADC drug through Glycotope licensing deal

Gatipotuzumab further fills out the Japanese pharma's pipeline of antibody-drug conjugates, which have seen increased investment as of late.

By Jacob Bell • July 30, 2018

WuXi and Antengene sign cancer manufacturing agreement

In a deal focusing on China and the Asia-Pacific, WuXi will provide CMC services from preclinical to commercial.

By Suzanne Elvidge • July 26, 2018

GSK teams up with 23andMe to boost R&D

As part of a broader restructuring, the British pharma hopes to tap 23andMe's genetic database to develop better drugs and more easily find patients.

By Lisa LaMotta • July 25, 2018

AstraZeneca offloads Atacand in Europe for $200M

While cardiovascular remains a focus for the British pharma, part of its aging Atacand franchise didn't make the cut amid a company-wide portfolio pruning.

By Suzanne Elvidge • July 25, 2018

Chiesi adds US rights to Fabry disease drug in Protalix deal

While the upfront payment is small, Protalix could receive nearly $800 million in milestone payments if the late-stage candidate is successfully marketed. 

By Suzanne Elvidge • July 25, 2018

Sobi picks up Novimmune drug, strengthening pipeline

Novimmune has already submitted the drug in question, emapalumab, for U.S. approval in a rare immune disease, with a decision expected by year's end.

By Suzanne Elvidge • July 23, 2018

Sangamo to buy TxCell, cell therapy tech in $84M deal

It's a bet on the promise of using CAR technology to treat immunological diseases rather than cancer. 

By Ned Pagliarulo • July 23, 2018

Cambrex builds CDMO offerings with $425M Halo buy

By buying Halo, the API maker will add capabilities in specialized dosage forms as well as acquire two manufacturing plants. 

By Lisa LaMotta • July 23, 2018

Roche bets over $1B on tech that lets patients swallow antisense drugs

A $36 million upfront payment gives Roche access to PureTech's platform, which aims to package and shepherd complex drugs through the digestive system without degrading.

By Jacob Bell • July 20, 2018

Gilead strikes deal to further strengthen cell therapy capabilities

Kite Pharma, the big biotech's CAR-T subsidiary, has taken a stake in privately-held biotech Gadeta to develop gamma delta TCR therapies.

By Barbara Boughton • July 20, 2018

PTC Therapeutics inks purchase deal for Agilis

The buy adds a gene therapy platform and four gene therapy programs to the pipeline of the RNA biology-focused company.

By Suzanne Elvidge • July 20, 2018

Novartis picks up IL-17 inhibitor in deal worth over $1B

The deal is aimed at bolstering an immunology pipeline that's thin outside of Cosentyx.

By Lisa LaMotta • July 19, 2018

Eusa acquires rights to J&J rare disease drug Sylvant

While J&J doesn't break out sales of Sylvant, Eusa claims the drug has seen "rapid revenue growth." 

By Barbara Boughton • July 19, 2018

Mesoblast gets access to China through deal with Tasly

Through a $65 million deal, Mesoblast will expand into the Chinese market, while Tasly moves beyond its focus on traditional Chinese medicines.

By Suzanne Elvidge • July 18, 2018

J&J taps German Merck to market Invokana in China

Diabetes became a major health issue in China over last few decades. Though that offers a big market opportunity, commercializing products remains tricky.

By Suzanne Elvidge • July 13, 2018

WuXi adds to its dealmaking hot streak

A new manufacturing agreement with Immune Therapeutics tasks WuXi with supplying the biotech's lead antibody.

By Suzanne Elvidge • July 12, 2018

BioCryst nixes merger, sending Idera stock down

Both companies are trying to find a path forward after plans to join were dropped. 

By Suzanne Elvidge • July 12, 2018

Otsuka drops $430M to beef up antibody drug development

An acquisition deal for Visterra hands the Japanese pharma a slate of preclinical candidates and access to the target's Hierotope technology.

By Jacob Bell • July 11, 2018

Pfizer rejiggers business units

After moving around some puzzle pieces, the big pharma will have three distinct units operating independently. 

By Lisa LaMotta • July 11, 2018

Genevant inks development deal with BioNTech

The "Vant" focused on RNA therapeutics has agreed to co-develop mRNA drugs for rare diseases.

By Lisa LaMotta • July 10, 2018

Healthcare startups raise $15B through first half of 2018

Funding was spread over fewer companies than last year, however, according to a Pitchbook analysis for Forbes.

By Meg Bryant • July 10, 2018

Axovant parades new preclinical therapy, much to investor delight

A licensing deal with Benitec Biopharma provides Axovant a much-needed pipeline expansion, as well as underscores its interest in gene therapy.

By Jacob Bell • July 9, 2018

Novartis backs out of Aveo deal, but dispute continues

The Swiss pharma cited changes in management and strategy for the move, yet Aveo has some unfinished business. 

By Suzanne Elvidge • July 5, 2018

Catalent expands with $133M deal for Juniper

Acquiring the Boston-based company will hand Catalent a clinical development and manufacturing center in the U.K.

By Ned Pagliarulo • July 3, 2018